Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Phase Ib/II, open-label, dose escalation and expansion clinical study of ADG106 in combination with KEYTRUDA® (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies

X
Trial Profile

A Global Phase Ib/II, open-label, dose escalation and expansion clinical study of ADG106 in combination with KEYTRUDA® (pembrolizumab) in advanced or metastatic solid and/or hematological malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADG 106 (Primary) ; Pembrolizumab (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KEYNOTE-D12
  • Most Recent Events

    • 30 Aug 2022 According to an Adagene media release. given the prioritization of its two anti-CTLA-4 clinical programs and potential of its next generation anti-CD137 therapy, ADG206, Adagene does not intend to proceed with the current trial.
    • 30 Aug 2022 Status changed from planning to discontinued, according to an Adagene media release.
    • 26 Aug 2021 According to an Adagene media release, company to implement biomarker-enriched tumor targeting strategy for this trial in the U.S. and Asia Pacific (APAC). Data from this trial anticipated in 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top